Double-layer drug-loaded microneedle for treating premature ovarian failure as well as preparation method and application of double-layer drug-loaded microneedle

By designing a double-layer hydrogel drug-loading microneedle, using the dual effects of tanshinone drugs and platelet-rich plasma, the drug release sequence is regulated, and the problem of single and poor results in the treatment of premature ovarian failure is solved, and a rapid rise is achieved The therapeutic effect of effective and long-term sustained release restores ovarian function and tissue health.

CN119055581AInactive Publication Date: 2024-12-03BEOGENE BIOTECH GUANGZHOU

Patent Information

Application Number
CN202411253415.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing technology cannot effectively treat premature ovarian failure. Traditional treatment methods can only relieve symptoms and fail to fundamentally improve ovarian reserve function. Moreover, the type of microneedle loading drugs is single, making it difficult to meet the treatment needs.

Method used

A double-layer hydrogel drug-loaded microneedle was designed, with the outer needle tip loading tanshinone drugs, and the inner needle tip loading platelet-rich plasma. By regulating the drug release sequence, natural polymer materials such as silk fibroin and gelatin are used as skeleton materials. , ensure the mechanical properties and drug stability of microneedles.

Benefits of technology

It achieves rapid onset and long-term sustained release of the drug, restores ovarian function, reduces apoptosis of granule cells, protects the ovarian microenvironment, promotes follicle maturation, reduces ovarian tissue fibrosis, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055581A_ABST
    Figure CN119055581A_ABST
Patent Text Reader

Abstract

The invention relates to a double-layer drug-loaded microneedle for treating premature ovarian failure as well as a preparation method and application of the double-layer drug-loaded microneedle. The double-layer drug-loading microneedle comprises a substrate layer and a needle tip arranged on the substrate layer, and the needle tip sequentially comprises an outer-layer needle tip and an inner-layer needle tip from outside to inside; the outer-layer needle tip comprises an outer-layer microneedle framework material and a tanshinone medicine loaded on the outer-layer microneedle framework material; the inner-layer needle tip comprises an inner-layer microneedle framework material and platelet-rich plasma loaded on the inner-layer microneedle framework material. According to the microneedle, the double-layer needle tip structure is utilized, the drug release sequence is regulated and controlled, the better treatment release effect can be achieved, the mechanical performance of the microneedle can be guaranteed, meanwhile, the drug carrying variety of the microneedle can be increased, and the microneedle can take effect quickly and can be slowly released for a long time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical biomaterials, and in particular to a double-layer hydrogel drug-loaded microneedle for treating premature ovarian failure, and a preparation method and application thereof. Background Art

[0002] Premature ovarian failure (POF) refers to an ovarian dysfunction disease with amenorrhea, infertility, and excessive gonadotropin levels as the main clinical manifestations in women before the age of 40. At present, the specific cause of most POF patients has not been clarified. It is generally believed that it is mainly related to genetic factors, autoimmune factors, iatrogenic factors, and environmental factors. Granulosa cells (GCs) are the basic functional units of the ovary. They are located outside the zona pellucida of the oocyte and provide nutrition and information exchange for the oocyte through gap junctions. Their proliferation, differentiation, and apoptosis directly affect the development of the oocyte and the maturation of the follicle. Most studies believe that the dysfunction of GCs can directly or indirectly cause the acceleration of follicular atresia, thereby leading to POF. At present, there is no effective treatment for POF patients to restore ovarian reserve function. Existing clinical treatments can only relieve the symptoms of POF patients and meet the fertility needs of some patients, but fail to fundamentally improve the ovarian reserve and promote follicle regeneration. There are also ethical disputes and adverse reactions.

[0003] Microneedles are manufactured using micromachining technology. They can penetrate biomembranes to form needle-shaped protrusions with micrometer-scale drug channels, which can increase drug penetration. They have the advantages of minimally invasive, painless, and autonomous drug administration. They are widely studied for transdermal delivery and vaccination of biomacromolecule drugs. Microneedles are mainly divided into solid microneedles, coated microneedles, hollow microneedles, soluble microneedles, and swollen microneedles. Among them, soluble microneedles do not need to be removed after penetrating the biomembrane. The polymer materials used are non-toxic and degradable, which can achieve immediate release of drugs. If necessary, they can also form a reservoir with drugs to slowly and continuously release drugs. In recent years, soluble microneedles have been used as long-acting sustained-release preparations in Alzheimer's disease, cancer, immunity, and contraception, but there are few reports on related research for POF treatment. In addition, the effective drugs of soluble microneedles are usually limited to the needle tip of the microneedle. The addition of drugs will weaken the mechanical properties of the microneedle, and the type of drug loaded in a single microneedle is single, which is difficult to meet the drug delivery needs of POF treatment. Therefore, how to design soluble drug-loaded microneedles, increase the types of drugs loaded while ensuring the mechanical properties of the microneedles, and achieve rapid onset of action while achieving long-term sustained release is an urgent problem to be solved in the treatment of POF with soluble microneedles. Summary of the invention

[0004] In view of the above-mentioned deficiencies in the prior art, the present invention provides a double-layer hydrogel drug-loaded microneedle for treating premature ovarian failure, and a preparation method and application thereof.

[0005] The specific technical scheme of the present invention is as follows:

[0006] In a first aspect of the present invention, a microneedle for treating premature ovarian failure is provided, comprising a basal layer and a needle tip disposed on the basal layer, wherein the needle tip comprises an outer needle tip and an inner needle tip from the outside to the inside; the outer needle tip comprises an outer microneedle skeleton material and a tanshinone drug loaded thereon; the inner needle tip comprises an inner microneedle skeleton material and platelet-rich plasma (PRP) loaded thereon.

[0007] The microneedle tip contains a drug and a microneedle skeleton material, wherein the drug is a drug in an amount sufficient to treat premature ovarian failure, and the microneedle skeleton material is generally a natural polymer material. The drug in an amount sufficient to treat premature ovarian failure is mixed with a natural polymer material to prepare the needle tip, which not only ensures that the microneedle patch meets the drug content required for POF treatment, but also achieves the mechanical properties of penetrating tissue biomembranes. The natural polymer material has biocompatibility and biodegradability, can stabilize the loaded drug, and the formed microneedle preparation can be stored at room temperature.

[0008] Moreover, the needle tip includes an inner needle tip and an outer needle tip, and the outer needle tip includes an outer microneedle skeleton material and tanshinone drugs loaded thereon; the inner needle tip includes an inner microneedle skeleton material and platelet-rich plasma (PRP) loaded thereon. The tanshinone drugs loaded on the outer layer of the needle tip are released first to reduce granulosa cell apoptosis, thereby restoring ovarian function; on the basis of restoring ovarian function, the inner layer of the needle tip slowly and continuously releases PRP to protect ovarian function and stabilize the ovarian microenvironment, provide conditions for follicle maturation, further restore the tissue morphology, elasticity and toughness of the ovary, and reduce ovarian tissue fibrosis. By designing the inner and outer needle tip structures, the order of drug release can be regulated to achieve a better release effect.

[0009] Preferably, the outer microneedle skeleton material comprises silk fibroin, and more preferably, the silk fibroin is methacrylylated silk fibroin (SFMA). Silk fibroin has properties suitable for microneedle manufacturing, including full water treatment, mechanical strength, biocompatibility, and the ability to stabilize and control the release of various drugs.

[0010] Preferably, the inner layer microneedle skeleton material comprises gelatin, and more preferably gelatin methacryloyl (GelMA).

[0011] Preferably, the tanshinone drug is selected from at least one of the following: tanshinone ⅡA (TSⅡA), cryptotanshinone. More preferably, the tanshinone drug is TSⅡA.

[0012] Preferably, the substrate layer is a dissolvable substrate layer.

[0013] Further preferably, the base layer comprises two or more of the following: polysaccharides (e.g., dextran); disaccharides (e.g., sucrose, maltose and trehalose); polymers (e.g., methylcellulose, polyethylene glycol (PEG), carboxymethylcellulose (CMC), polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and hyaluronate; proteins (e.g., gelatin).

[0014] Further preferably, the base layer comprises one or more of the following: gelatin, dextran, polyethylene glycol (PEG) (e.g., including low molecular weight PEG), sucrose, trehalose, maltose, carboxymethyl cellulose (CMC), polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hyaluronate and methyl cellulose.

[0015] Further preferably, the base layer comprises gelatin, polyethylene glycol (PEG) (eg, including low molecular weight PEG), polyvinyl alcohol (PVA) and hyaluronate.

[0016] Further preferably, the base layer comprises hyaluronate, such as sodium hyaluronate (HA), potassium hyaluronate and the like.

[0017] Preferably, the plurality of needle tips are arranged in a matrix on the base layer.

[0018] Preferably, the needle tip is conical, and may be a circular cone or a four-sided cone.

[0019] The present invention also provides a method for preparing the above-mentioned microneedle for treating premature ovarian failure, comprising the following steps:

[0020] S1 Preparation of needle tip:

[0021] S11 dissolves tanshinone drugs and outer microneedle skeleton materials in water to form a mixed solution, adds it to the microneedle mold, removes bubbles in vacuum, and solidifies to form the outer needle tip structure.

[0022] Preferably, the mixed solution contains 5-25wt% SFMA and 0.1-10.0mg / mL TSⅡA;

[0023] Further preferably, the mixed solution contains 10-20 wt% SFMA and 0.5-5.0 mg / mL TSⅡA;

[0024] S12: dissolving the platelet-rich plasma and the inner layer microneedle skeleton material in water to form a mixed solution, adding the mixed solution to the microneedle mold in S11, vacuum degassing, and curing to form an inner layer needle tip structure, thereby obtaining a double-layer structure needle tip;

[0025] Preferably, the mixed solution contains 5-15wt% GelMA and 5-15μL / mL PRP;

[0026] Further preferably, it contains 8-12wt% GelMA and 8-10μL / mL PRP;

[0027] S2 Preparation of base layer:

[0028] Adding the aqueous solution of the base layer material into the S12 microneedle mold, drying to form a base, and demoulding to obtain the double-layer drug-loaded microneedle;

[0029] Preferably, the aqueous solution of the substrate material contains 1-8 wt% HA;

[0030] Preferably, the drying is carried out at 4° C. for 48-72 hours.

[0031] Preferably, in order to facilitate curing, a photoinitiator, such as LAP, etc., may be added to the mixed solution in steps S11 and S12 to cure by photocrosslinking. The amount of photoinitiator added may be 0.05-0.25 wt%.

[0032] The present invention also provides a transdermal drug preparation, comprising the above-mentioned double-layer drug-loaded microneedle or the double-layer drug-loaded microneedle prepared by the above-mentioned preparation method.

[0033] The beneficial effects of the present invention are:

[0034] The present invention designs soluble drug-loaded microneedles and utilizes a double-layer needle tip structure to regulate the order of drug release. The outer layer of tanshinone drugs is released first to reduce granulosa cell apoptosis, thereby restoring ovarian function. On the basis of restoring ovarian function, the inner layer of the needle tip slowly and continuously releases PRP to protect ovarian function and stabilize the ovarian microenvironment, providing conditions for follicle maturation, further restoring the tissue morphology, elasticity and toughness of the ovaries, and reducing ovarian tissue fibrosis. Better therapeutic release effects can be achieved. Further, by optimizing the skeleton material composition, the types of drugs loaded can be increased while ensuring the mechanical properties of the microneedles, so that the microneedles can take effect quickly and have long-term sustained release. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 is a microneedle fluorescence image of the hydrogel microneedle of the present invention;

[0036] Figure 2 is a microneedle SEM image of the hydrogel microneedle of the present invention;

[0037] Figure 3 is the single needle compressive strength of the hydrogel microneedle of the present invention;

[0038] Figure 4 The results of H&E staining of the longitudinal section of the needle tip of the hydrogel microneedle of the present invention piercing the pig skin;

[0039] Figure 5 This is a layer scanning image of the hydrogel microneedle of the present invention piercing into pig skin, with a scanning interval of 10 μm;

[0040] Figure 6 The CCK8 test results of the biocompatibility of the hydrogel microneedle of the present invention;

[0041] Figure 7 The results of live and dead cell staining for the biocompatibility of the hydrogel microneedles of the present invention are shown;

[0042] Figure 8 The results of the in vitro experiment of the hydrogel microneedles of the present invention promoting HUVEC cells to form blood vessels;

[0043] Fig. 9 It is the quantitative evaluation result of the total length of nodes and blood vessels in the vascularized network structure in the angiogenesis-promoting experiment of the hydrogel microneedle of the present invention;

[0044] Fig.10 The results of ELISA detection of VEGF and PDGF-BB protein levels in the angiogenesis-promoting experiment of the hydrogel microneedle of the present invention;

[0045] Fig.11 The results of qPCR analysis of CDH5, PECAM-1 and VEGFA gene expression levels in the angiogenesis-promoting experiment of the hydrogel microneedle of the present invention;

[0046] Fig.12 The results of CCK8 activity detection of ROS-damaged HUVEC cells treated with the hydrogel microneedles of the present invention;

[0047] Fig.13 These are the results of fluorescent staining of live and dead cells of ROS-damaged HUVEC cells treated with the hydrogel microneedles of the present invention. DETAILED DESCRIPTION

[0048] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0050] Unless otherwise specified, the reagents, materials, and equipment used in the examples of the present invention are all commercially available; the test methods, unless otherwise specified, are all conventional test methods in the art.

[0051] Example 1 Gel concentration screening experiment

[0052] Referring to Table 1, SFMA / / GelMA hydrogel microneedles (Gel) without drug loading were prepared by preparing gel aqueous solutions of different concentrations to explore the optimal gel aqueous solution concentration combination.

[0053] The preparation method of SFMA / / GelMA hydrogel microneedles (Gel) is as follows:

[0054] S1 Preparation of needle tip

[0055] S11: SFMA is dissolved in deionized water to form a SFMA hydrogel solution, and a photoinitiator LAP is added.

[0056] The SFMA hydrogel solution was added to the PDMS microneedle mold and the mold was transferred to a custom acrylic vacuum degassing box. The vacuum in the vacuum degassing box was adjusted to -100 kPa to remove bubbles and fill the mold with the hydrogel pre-liquid. After the microneedle tip was completely filled, the excess solution was removed and the microneedle tip was cross-linked to form a hydrogel, thereby forming the outer needle tip structure.

[0057] S12: dissolving GelMA in deionized water to form a GelMA hydrogel solution, and adding a photoinitiator LAP.

[0058] Then, the GelMA hydrogel solution is continuously added to the PDMS microneedle mold, and vacuum and degassing are performed. After the microneedle tip is completely filled, the excess solution is removed, and the microneedle tip is cross-linked to form a hydrogel, which is solidified to form an inner layer needle tip structure, thereby obtaining a double-layer structure needle tip;

[0059] S2 Preparation of base layer:

[0060] HA was dissolved in deionized water to obtain a HA solution.

[0061] The HA aqueous solution was added to the backing layer of the mold and dried at 4° C. for 72 hours before demolding to form a substrate, and then demolded to obtain the double-layer hydrogel microneedle.

[0062] Table 1 Components of hydrogel solutions in each experiment of Example 1

[0063]

[0064] Figure 1 and Figure 2 Fluorescence microscope and SEM images of the obtained hydrogel microneedles.

[0065] It can be seen that in the obtained sample, the microneedle double-layer structure is obvious, and the fluorescence is evenly distributed in the microneedle, indicating that the obtained microneedle has drug-carrying capacity. Figure 2 The SEM image of the microneedle can more clearly observe the pyramid-shaped structure of the sharp needle tip. The hydrogel microneedle with a pyramid shape and a sharper needle tip can show a better skin insertion effect.

[0066] Figure 3 The single needle compressive strength statistical results of the needle tip compression strength test of the hydrogel microneedles prepared from the obtained hydrogel solutions of different concentrations. The specific test method is as follows: The microneedle sample is placed on the sample table with the tip facing up. Then the tip is pressed at a constant rate of 0.05 mm / s by a universal testing machine. Five microneedles are tested in each embodiment, and the average value is taken.

[0067] The breaking force of a single microneedle exceeds the minimum force (0.03N) required to penetrate biological barriers such as the skin, and can be used to deliver (e.g., administer) an effective amount of therapeutic agents such as anticancer agents, immunomodulators, or a combination thereof across biological barriers (e.g., skin layers, cell membranes, mucus surfaces, oral cavity, skin lesions, tumors, or buccal cavities). It can be seen that the microneedles formed after curing the 10-20wt% SFMA and 8-12wt% GelMA gel aqueous solution have good compressive resistance. It can meet the requirements.

[0068] Figure 4 and Figure 5 The hydrogel microneedles obtained in Examples 1-3 were tested for their puncture effect on pig skin. After the hydrogel microneedles were inserted into the pig skin, H&E staining was performed on the pig skin to observe the puncture effect of the microneedle tip on the skin. Figure 4 It can be seen that the needle tip can pierce the skin, and part of the microneedle remains in the skin, with a good puncture effect. The retention of hydrogel microneedles in pig skin was observed using a laser confocal scanning microscope. Figure 5 The layer scanning image showed that each microneedle left a nearly square hole on the pig skin, and the depth of the microneedle piercing in the skin could reach 290μm.

[0069] In subsequent experiments, based on the screening experiment results, the concentration of the hydrogel solution in Examples 1-3 was selected as the standard, and drugs were added to conduct experiments.

[0070] Example 2 Drug loading experiment

[0071] Referring to Table 2, drug-loaded microneedles were prepared by loading drugs at different concentrations, and the appropriate drug loading concentration was screened by testing the drug loading and release properties of the microneedles.

[0072] The prepared microneedle samples are shown in Table 2.

[0073] Table 2 Drug loading concentration in each experiment of Example 2

[0074]

[0075]

[0076] A double-layer drug-loaded microneedle for treating premature ovarian failure - SFMA / TSⅡA / / GelMA / PRP microneedle, including a basal layer and a needle tip arranged on the basal layer, the needle tip including an outer needle tip and an inner needle tip from the outside to the inside; the outer needle tip includes an outer microneedle skeleton material and a tanshinone drug TSⅡA loaded thereon; the inner needle tip includes an inner microneedle skeleton material and platelet-rich plasma PRP loaded thereon.

[0077] The outer layer microneedle skeleton material includes SFMA, the inner layer microneedle skeleton material includes GelMA, and the base layer includes HA.

[0078] The preparation method of the microneedle is as follows, comprising the steps of:

[0079] S1 Preparation of needle tip

[0080] S11 SFMA is dissolved in deionized water to form a 10 wt% SFMA hydrogel solution, and 0.2 wt% of a photoinitiator LAP is added, and then 0.1-10.0 mg / mL TSⅡA is added to obtain a SFMA / TSⅡA mixed solution.

[0081] The SFMA / TSⅡA mixed solution was added to the PDMS microneedle mold and the mold was transferred to a custom acrylic vacuum degassing box. The vacuum degree in the vacuum degassing box was adjusted to -100 kPa to remove bubbles and fill the mold with the hydrogel pre-liquid. After the microneedle tip was completely filled, the excess solution was removed and the microneedle tip was cross-linked to form a hydrogel, thereby forming the outer needle tip structure.

[0082] S12: GelMA is dissolved in deionized water to form a 10 wt% GelMA hydrogel solution, and 0.2 wt% of photoinitiator LAP is added, and then 5-15 μL / mL of PRP is added to obtain a GelMA / PRP mixed solution.

[0083] Then, the GelMA / PRP mixed solution is continuously added to the PDMS microneedle mold, and vacuum and degassing are performed. After the microneedle tip is completely filled, the excess solution is removed, and the microneedle tip is cross-linked to form a hydrogel, which is solidified to form an inner layer needle tip structure, thereby obtaining a double-layer structure needle tip;

[0084] S2 Preparation of base layer:

[0085] HA was dissolved in deionized water to obtain a 5 wt% HA solution.

[0086] The HA aqueous solution was added to the backing layer of the mold and dried at room temperature for 48 hours before demolding to form a substrate, and demolding was performed to obtain the double-layer drug-loaded microneedles.

[0087] The drug (TSⅡA) loading performance of the microneedle samples with different drug loading concentrations obtained in Example 2 was tested. The results showed that Example 2-2 had the best drug loading and release performance, with a loading amount of TSⅡA of 67.56±2.82 μg / needle. The drug (TSⅡA) release performance of the microneedle was tested in PBS at 37°C. The results showed that TSⅡA could be released for nearly 6 days, with a release rate of 91.05%, and 69.02% of TSⅡA was released within 24 hours.

[0088] Furthermore, a comparative example was set up with Example 2-2 as the standard to explore the synergistic therapeutic effect of the drugs.

[0089] Comparative Example 1: SFMA / TSⅡA / / GelMA hydrogel microneedle (Gel-TSⅡA)

[0090] The difference from Example 2-2 is that only the outer needle tip is loaded with the tanshinone drug TSⅡA. The specific preparation method can be found in Example 2.

[0091] Comparative Example 2 SFMA / / GelMA / PRP hydrogel microneedle (Gel-PRP)

[0092] The difference from Example 2-2 is that only the inner needle tip is loaded with PRP. The specific preparation method can be found in Example 2.

[0093] Test example:

[0094] 1. Microneedle biocompatibility test

[0095] The microneedle Gel obtained in Example 1-3, the microneedle (Gel-TSⅡA / PRP) obtained in Example 2-2, the microneedle (Gel-TSⅡA) obtained in Comparative Example 1, and the microneedle (Gel-PRP) obtained in Comparative Example 2 were tested for biological properties. The results are as follows: Figure 6 shown.

[0096] The CCK8 test results showed that pure hydrogel microneedles had no cytotoxicity to HUVEC cells. Moreover, the addition of drugs also had no cytotoxicity to HUVEC cells.

[0097] The live and dead cell staining results of the microneedles (Gel-TSⅡA / PRP) obtained in Example 2-2 are as follows: Figure 7 As shown, there was no obvious apoptosis in the cells, the cell viability was well maintained, and the microneedle had good biocompatibility.

[0098] 2. Test of the effect of treatment of premature ovarian failure

[0099] The microneedle Gel obtained in Example 1-3, the microneedle (Gel-TSⅡA / PRP) obtained in Example 2-2, the microneedle (Gel-TSⅡA) obtained in Comparative Example 1, and the microneedle (Gel-PRP) obtained in Comparative Example 2 were subjected to angiogenesis experiments. The results are shown in FIG. Figure 8 shown. Figure 8 It was shown that at 4 hours, no angiogenesis was observed in the control group and the Gel hydrogel group, but there was a tendency to form a vascular network. The hydrogels in the Gel-TSⅡA group and the Gel-PRP group promoted the formation of lumens around HUVECs, but the effect was weak. However, lumen formation was clearly observed in the Gel-TSⅡA / PRP group hydrogel, and angiogenesis was significantly better than that in the control group, indicating that TSⅡA and PRP can synergistically promote the formation of blood vessels in vitro. Quantitative analysis showed that the number of vascular connections and the total length of the hydrogel in the Gel-TSⅡA / PRP group increased significantly ( Fig. 9 ).like Fig.10 As shown in the figure, the protein expressions of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB (PDGF-BB) were similar. Compared with the blank control group of HUVECs without hydrogel extract, the expression of VEGF and PDGF-BB in the Gel-TSⅡA / PRP group was significantly increased. qRT-PCR was used to detect the expression of mRNA of angiogenesis-related markers after co-culture of hydrogel extract and HUVECs. Fig.11 As shown in the figure, the expression levels of vascular endothelial cadherin (CDH5), platelet endothelial cell adhesion molecule-1 (PECAM-1), and vascular endothelial growth factor A (VEGFA) mRNA were higher than those in the control group. These results indicate that Gel-TSⅡA / PRP plays an important role in promoting the expression of angiogenic marker mRNA, which helps to restore ovarian function and stabilize the ovarian microenvironment.

[0100] H2O2 induced HUVEC cell damage and established an in vitro high ROS environment to evaluate the protective effect of TSⅡA and PRP against ROS. After the cells damaged by H2O2 were cultured with hydrogel extract, the cell survival rate of the SFMA / GelMA-TSⅡA / PRP group was significantly higher than that of the other groups ( Fig.12 The live and dead cell fluorescence staining results are also displayed intuitively ( Fig.13 ), after TSⅡA and PRP treatment, the number of dead cells was significantly reduced, and the cells as a whole showed better vitality. Animal results showed that hydrogel microneedles can quickly reduce granulosa cell apoptosis, restore the tissue morphology, elasticity and toughness of the ovaries, and effectively reduce ovarian tissue fibrosis.

[0101] The above comparative test results show that by setting up a double-layer structure and regulating the order of drug release, the outer layer loaded with tanshinone drugs is released first, which can reduce granulosa cell apoptosis and thus restore ovarian function; on the basis of restoring ovarian function, the inner layer of the needle tip slowly and continuously releases PRP to protect ovarian function and stabilize the ovarian microenvironment, providing conditions for the development and maturation of follicles, further restoring the tissue morphology, elasticity and toughness of the ovaries, reducing ovarian tissue fibrosis, and achieving better therapeutic release effects.

[0102] The technical features of the above-mentioned embodiments can be combined arbitrarily. To make the description concise, all possible combinations of the technical features in the above-mentioned embodiments are not described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.

Claims

1. A double-layer drug-loaded microneedle for treating premature ovarian failure, characterized in that: The double-layer drug-loaded microneedle includes a base layer and a needle tip arranged on the base layer, and the needle tip includes an outer needle tip and an inner needle tip from the outside to the inside; the outer needle tip includes an outer microneedle skeleton material and a tanshinone drug loaded thereon; the inner needle tip includes an inner microneedle skeleton material and platelet-rich plasma loaded thereon.

2. The double-layer drug-loaded microneedle according to claim 1, characterized in that: The outer layer microneedle skeleton material comprises silk fibroin; preferably, the silk fibroin is methacrylylated silk fibroin.

3. The double-layer drug-loaded microneedle according to claim 1, characterized in that: The inner layer microneedle skeleton material comprises gelatin; preferably, the gelatin is methacrylated gelatin.

4. The double-layer drug-loaded microneedle according to claim 1, characterized in that: The tanshinone drug is selected from at least one of the following: tanshinone ⅡA, cryptotanshinone; preferably, the tanshinone drug is tanshinone ⅡA.

5. The double-layer drug-loaded microneedle according to claim 1, characterized in that: The base layer is a soluble base layer.

6. The double-layer drug-loaded microneedle according to claim 5, characterized in that: The base layer comprises one or more of the following: polysaccharides, disaccharides, polymers, polyvinyl pyrrolidone, polyvinyl alcohol, hyaluronate, proteins; Preferably, the base layer comprises one or more of the following: gelatin, dextran, polyethylene glycol, sucrose, trehalose, maltose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, hyaluronate and methylcellulose; Preferably, the base layer comprises one or more of the following: gelatin, polyethylene glycol, polyvinyl alcohol and hyaluronate; Preferably, the base layer comprises hyaluronate.

7. The method for preparing the double-layer drug-loaded microneedle for treating premature ovarian failure according to any one of claims 1 to 6, characterized in that: The following steps are involved: S1 Preparation of needle tip: S11 dissolves tanshinone drugs and outer microneedle skeleton materials in water to form a mixed solution, adds it to the microneedle mold, removes bubbles in vacuum, and solidifies to form the outer needle tip structure. S12: dissolving platelet-rich plasma and inner-layer microneedle skeleton material in water to form a mixed solution, adding the solution to the microneedle mold in S11, vacuum degassing, and curing to form an inner-layer needle tip structure, thereby obtaining a double-layer structure needle tip; S2 Preparation of base layer: The aqueous solution of the base layer material is added to the S12 microneedle mold, dried to form a base, and demoulded to obtain the double-layer drug-loaded microneedle.

8. The preparation method according to claim 7, characterized in that: The mixed solution of step S11 comprises 5-25wt% of methacryloylated silk fibroin and 0.1-10.0mg / mL of tanshinone ⅡA; the mixed solution of step S12 comprises 5-15wt% of methacryloylated gelatin and 5-15μL / mL of platelet-rich plasma; Preferably, the mixed solution of step S11 contains 10-20wt% of methacrylylated silk fibroin and 0.5-5.0mg / mL of tanshinone ⅡA; the mixed solution of step S12 contains 8-12wt% of methacrylylated gelatin and 8-10μL / mL of platelet-rich plasma.

9. The preparation method according to claim 7, characterized in that: In the step S2, the aqueous solution of the base layer material contains 1-8 wt % of sodium hyaluronate.

10. A transdermal drug preparation, comprising the double-layer drug-loaded microneedle according to any one of claims 1 to 6 or the double-layer drug-loaded microneedle prepared by the preparation method according to any one of claims 7 to 9.

Citation Information

Patent Citations

  • Gelatin-silk fibroin hydrogel loaded with adipose-derived stem cells and plasma as well as preparation method and application of gelatin-silk fibroin hydrogel

    CN113045717A

  • Effervescent soluble microneedle patch of platelet-rich plasma and preparation method of effervescent soluble microneedle patch

    CN116251079A

  • Microneedle patch with needle tip swelled and enriched medicine as well as preparation method and application of microneedle patch

    CN117323289A

  • Double-layer drug-loaded microneedle for treating vitiligo as well as preparation method and application of double-layer drug-loaded microneedle

    CN118078762A

  • Stable platelet- rich-plasma compositions and methods of use

    WO2014126931A1

Cited By

  • Honokiol-loaded microneedle as well as preparation method and application thereof

    CN120284843A